Zhitong Financial App News, and Platinum Pharmaceutical-B (02142.HK) announced that China's National Drug Administration (NMPA) has approved the marketing of bartolizumab injection (subcutaneous injection) (170 mg (1 mL) /bottle) to be used in combination with conventional medications to treat adult systemic myasthenia gravis (GmG) patients with positive anti-acetylcholine receptor (AChR) antibodies. Bartolizumab (HBM9161) is the company's core product under Chapter 18A of the Listing Rules. Bartolizumab subcutaneous injection is the Group's first approved product. It is also the first anti-neonatal Fc receptor (FcRn) therapy to complete clinical development for GMG patients in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.